Randomised clinical trial: The clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 12, 2011, Pages 1311-1321

  Zakko, S ^a   Barton, G ^b   Weber, E ^c   Dunger Baldauf, C ^c   Ruhl A ^c  

^a Bristol Hospital   (United States)

^b Arkansas Gastroenterology PA   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DNK 333; PLACEBO; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BACKACHE; BLOATING; CONSTIPATION; CONTROLLED STUDY; DEFECATION URGENCY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; FATIGUE; FEMALE; FLATULENCE; HUMAN; IRRITABLE COLON; LOOSE FECES; MAJOR CLINICAL STUDY; MORNING DOSAGE; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; PATIENT COMPLIANCE; PATIENT SATISFACTION; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; AZA COMPOUNDS; BENZAMIDES; DIARRHEA; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; MIDDLE AGED; PLACEBOS; RECEPTORS, TACHYKININ; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79956138710     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04656.x     Document Type: Article

References (34)

1. Sperber AD, Shvartzman P, Friger M, Fich A,. A comparative reappraisal of the Rome II and Rome III diagnostic criteria: are we getting closer to the 'true' prevalence of irritable bowel syndrome? Eur J Gastroenterol Hepatol 2007; 19: 441-7. (Pubitemid 46725749)
2. Minocha A, Johnson WD, Abell TL, Wigington WC,. Prevalence, sociodemography, and quality of life of older versus younger patients with irritable bowel syndrome: a population-based study. Dig Dis Sci 2006; 51: 446-53.
3. Hungin AP, Chang L, Dennis EH, Barghout V,. Irritable bowel syndrome in the United States: symptom patterns and impact. Aliment Pharmacol Ther 2005; 21: 1365-75. (Pubitemid 40813683)
4. Saito YA, Schoenfeld P, Locke GR III,. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 2002; 97: 1910-5.
5. Wilson A, Longstreth GF, Knight K, et al. Quality of life in managed care patients with irritable bowel syndrome. Manag Care Interface 2004; 17: 24-8, 34.
6. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
7. Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead W,. Rome II: The Functional Gastrointestinal Disorders. McLean, VA: Degnon Associates, Inc., 2000.
8. Drossman DA, Corazziari E, Delvaux M, et al. Rome III. The Functional Gastrointestinal Disorders. McLean, VA: Degnon Associates, Inc., 2006.
9. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45 (Suppl 2): II43-7. (Pubitemid 29434812)
10. Chang L, Ameen VZ, Dukes GE, et al. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol 2005; 100: 115-23. (Pubitemid 41623278)
11. Cain KC, Headstrom P, Jarrett ME, et al. Abdominal pain impacts quality of life in women with irritable bowel syndrome. Am J Gastroenterol 2006; 101: 124-32. (Pubitemid 43381719)
12. Olden K, DeGarmo RG, Jhingran P, et al. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2002; 97: 3139-46. (Pubitemid 35424587)
13. Chang L, Chey WD, Harris L, et al. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol 2006; 101: 1069-79. (Pubitemid 43725322)
14. Krause R, Ameen V, Gordon SH, et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol 2007; 102: 1709-19. (Pubitemid 47206697)
15. Drossman DA, Whitehead W, Camilleri M,. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 1997; 112: 2120-37. (Pubitemid 27240803)
16. Steens J, van der Schaar PJ, Penning C, Brussee J, Masclee AA,. Compliance, tone and sensitivity of the rectum in different subtypes of irritable bowel syndrome. Neurogastroenterol Motil 2002; 14: 241-7. (Pubitemid 34639451)
17. Lee KJ, Kim JH, Cho SW,. Relationship of underlying abnormalities in rectal sensitivity and compliance to distension with symptoms in irritable bowel syndrome. Digestion 2006; 73: 133-41. (Pubitemid 44155915)
18. Dunlop SP, Hebden J, Campbell E, et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006; 101: 1288-94. (Pubitemid 43829995)
19. Zar S, Benson MJ, Kumar D,. Rectal afferent hypersensitivity and compliance in irritable bowel syndrome: differences between diarrhoea- predominant and constipation-predominant subgroups. Eur J Gastroenterol Hepatol 2006; 18: 151-8. (Pubitemid 43361600)
20. Lordal M, Navalesi G, Theodorsson E, Maggi CA, Hellstrom PM,. A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine. Br J Pharmacol 2001; 134: 215-23. (Pubitemid 32835485)
21. Lecci A, Capriati A, Maggi CA,. Tachykinin NK2 receptor antagonists for the treatment of irritable bowel syndrome. Br J Pharmacol 2004; 141: 1249-63. (Pubitemid 38638814)
22. Julia V, Su X, Bueno L, Gebhart GF,. Role of neurokinin 3 receptors on responses to colorectal distention in the rat: electrophysiological and behavioral studies. Gastroenterology 1999; 116: 1124-31. (Pubitemid 29203022)
23. Kamp EH, Beck DR, Gebhart GF,. Combinations of neurokinin receptor antagonists reduce visceral hyperalgesia. J Pharmacol Exp Ther 2001; 299: 105-13. (Pubitemid 32905124)
24. La JH, Kim TW, Sung TS, et al. Increase in neurokinin-1 receptor-mediated colonic motor response in a rat model of irritable bowel syndrome. World J Gastroenterol 2005; 11: 237-41.
25. Barreau F, Salvador-Cartier C, Houdeau E, Bueno L, Fioramonti J,. Long-term alterations of colonic nerve-mast cell interactions induced by neonatal maternal deprivation in rats. Gut 2008; 57: 582-90. (Pubitemid 351579968)
26. Gerspacher M, La VL, Mah R, et al. Dual neurokinin NK(1)/NK(2) antagonists: N-[(R,R)-(E)-1-arylmethyl-3-(2-oxo-azepan-3-yl)carbamoyl]allyl-N- methyl-3, 5-bis(trifluoromethyl)benzamides and 3-[N'-3,5-bis(trifluoromethyl) benzoyl-N-arylmethyl-N'-methylhydrazino]-N-[(R)-2-oxo-azepan-3-yl]propionamides. Bioorg Med Chem Lett 2001; 11: 3081-4.
27. Fozard J, Mazzoni L, Hoshiko K,. Effects of DNK333, a dual NK1/NK2 neurokinin receptor antagonist, on airway responsiveness induced by lipopolysaccharide or allergen challenge in the guinea-pig. Am J Respir Crit Care Med 2001; 163: A627.
28. Tough IR, Lewis CA, Fozard J, Cox HM,. Dual and selective antagonism of neurokinin NK(1) and NK(2) receptor-mediated responses in human colon mucosa. Naunyn Schmiedebergs Arch Pharmacol 2003; 367: 104-8. (Pubitemid 36286868)
29. Everhart J, Renault PF,. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology 1991; 100: 998-1005.
30. Camilleri M, Choi MG,. Review article: irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 3-15. (Pubitemid 27067330)
31. O'Donnell LJD, Virjee J, Heaton KW,. Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate. BMJ 1990; 300: 439-40. (Pubitemid 20069266)
32. Simpson EH,. The interpretation of interaction in contingency tables. J R Stat Soc Series B Stat Methodol 1951; 13: 238-41.
33. Talley NJ,. Evaluation of drug treatment in irritable bowel syndrome. Br J Clin Pharmacol 2003; 56: 362-9. (Pubitemid 37188130)
34. Joos GF, Vincken W, Louis R, et al. Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients. Eur Respir J 2004; 23: 76-81. (Pubitemid 38088500)